Robeco Institutional Asset Management B.V. grew its holdings in Hologic, Inc. (NASDAQ:HOLX) by 21.8% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 18,647 shares of the medical equipment provider’s stock after acquiring an additional 3,336 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Hologic were worth $797,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Parnassus Investments CA purchased a new position in shares of Hologic in the 3rd quarter valued at approximately $277,062,000. Koch Industries Inc. lifted its stake in shares of Hologic by 15,554.1% in the 2nd quarter. Koch Industries Inc. now owns 1,149,481 shares of the medical equipment provider’s stock valued at $1,125,000 after purchasing an additional 1,142,138 shares during the period. Point72 Asset Management L.P. purchased a new position in shares of Hologic in the 3rd quarter valued at approximately $39,041,000. Pictet Asset Management Ltd. lifted its stake in shares of Hologic by 50.3% in the 3rd quarter. Pictet Asset Management Ltd. now owns 2,912,338 shares of the medical equipment provider’s stock valued at $106,854,000 after purchasing an additional 974,325 shares during the period. Finally, Victory Capital Management Inc. lifted its stake in shares of Hologic by 16.8% in the 3rd quarter. Victory Capital Management Inc. now owns 5,856,778 shares of the medical equipment provider’s stock valued at $214,885,000 after purchasing an additional 844,426 shares during the period. Institutional investors and hedge funds own 92.77% of the company’s stock.

HOLX has been the subject of a number of research analyst reports. Zacks Investment Research cut Hologic from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Needham & Company LLC restated a “buy” rating and issued a $50.00 target price on shares of Hologic in a research note on Friday, November 3rd. Piper Jaffray Companies restated a “buy” rating and issued a $48.00 target price on shares of Hologic in a research note on Thursday, November 9th. Goldman Sachs Group upgraded Hologic from a “buy” rating to a “conviction-buy” rating and raised their target price for the company from $45.00 to $50.00 in a research note on Friday, December 8th. Finally, Cowen upgraded Hologic from a “market perform” rating to an “outperform” rating and set a $51.00 target price for the company in a research note on Monday, December 11th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Hologic currently has a consensus rating of “Buy” and an average price target of $48.79.

In related news, Director Elaine Ullian sold 9,282 shares of the firm’s stock in a transaction that occurred on Monday, November 13th. The stock was sold at an average price of $40.50, for a total transaction of $375,921.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Karleen Marie Oberton sold 1,023 shares of the firm’s stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $39.84, for a total value of $40,756.32. The disclosure for this sale can be found here. 0.79% of the stock is owned by company insiders.

Hologic, Inc. (HOLX) opened at $40.45 on Thursday. Hologic, Inc. has a 52-week low of $35.76 and a 52-week high of $46.80. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.61 and a current ratio of 0.79. The firm has a market capitalization of $11,676.25, a P/E ratio of 15.32, a P/E/G ratio of 1.89 and a beta of 0.77.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The company had revenue of $802.90 million during the quarter, compared to analyst estimates of $792.54 million. During the same quarter last year, the company earned $0.52 EPS. The firm’s revenue for the quarter was up 10.5% on a year-over-year basis. equities analysts forecast that Hologic, Inc. will post 2.18 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Hologic, Inc. (HOLX) Shares Bought by Robeco Institutional Asset Management B.V.” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.watchlistnews.com/hologic-inc-holx-shares-bought-by-robeco-institutional-asset-management-b-v/1852047.html.

Hologic Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.